Computational redesign of cytochrome P450 CYP102A1 for highly stereoselective omeprazole hydroxylation by UniDesign
Journal of Biological Chemistry · 2023-08 · 299 (8) · 105050
DOI: 10.1016/j.jbc.2023.105050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023-08. Verfasst von Xiaoqiang Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: xiaoqiah@umich.edu. Hauptthemen laut MEDLINE: Bacterial Proteins, Cytochrome P-450 Enzyme System, NADPH-Ferrihemoprotein Reductase, Omeprazole. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Cytochrome P450 CYP102A1 is a prototypic biocatalyst that has great potential in chemical synthesis, drug discovery, and biotechnology. CYP102A1 variants engineered by directed evolution and/or rational design are capable of catalyzing the oxidation of a wide range of organic compounds. However, it is difficult to foresee the outcome of engineering CYP102A1 for a compound of interest. Here, we introduce UniDesign as a computational framework for enzyme design and engineering. We tested UniDesign by redesigning CYP102A1 for stereoselective metabolism of omeprazole (OMP), a proton pump inhibitor, starting from an active but nonstereoselective triple mutant (TM: A82F/F87V/L188Q). To shift stereoselectivity toward (R)-OMP, we computationally scanned three active site positions (75, 264, and 328) for mutations that would stabilize the binding of the transition state of (R)-OMP while destabilizing that of (S)-OMP and picked three variants, namely UD1 (TM/L75I), UD2 (TM/A264G), and UD3 (TM/A328V), for experimentation, based on computed energy scores and models. UD1, UD2, and UD3 exhibit high turnover rates of 55 ± 4.7, 84 ± 4.8, and 79 ± 5.7 min-1, respectively, for (R)-OMP hydroxylation, whereas the corresponding rates for (S)-OMP are only 2.2 ± 0.19, 6.0 ± 0.68, and 14 ± 2.8 min-1, yielding an enantiomeric excess value of 92, 87, and 70%, respectively. These results suggest the critical roles of L75I, A264G, and A328V in steering OMP in the optimal orientation for stereoselective oxidation and demonstrate the utility of UniDesign for engineering CYP102A1 to produce drug metabolites of interest. The results are discussed in the context of protein structures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: xiaoqiah@umich.edu.
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: haom@umich.edu.
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- NIEHS NIH HHS
- University of Michigan
- National Institutes of Health
Zitieren
APA
Huang, X., Sun, Y., Osawa, Y., Chen, Y. E., & Zhang, H. (2023). Computational redesign of cytochrome P450 CYP102A1 for highly stereoselective omeprazole hydroxylation by UniDesign. Journal of Biological Chemistry, 299(8), 105050. https://doi.org/10.1016/j.jbc.2023.105050
Vancouver
Huang X, Sun Y, Osawa Y, Chen YE, Zhang H. Computational redesign of cytochrome P450 CYP102A1 for highly stereoselective omeprazole hydroxylation by UniDesign. Journal of Biological Chemistry. 2023;299(8):105050. doi:10.1016/j.jbc.2023.105050
BibTeX
@article{Huang2023,
author = {Huang, Xiaoqiang and Sun, Yudong and Osawa, Yoichi and Chen, Y Eugene and Zhang, Haoming},
title = {Computational redesign of cytochrome P450 CYP102A1 for highly stereoselective omeprazole hydroxylation by UniDesign},
journal = {Journal of Biological Chemistry},
year = {2023},
volume = {299},
number = {8},
pages = {105050},
doi = {10.1016/j.jbc.2023.105050}
}
EUVIMED